Skip to main content

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Portico NG Approval Study

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Portico NG Approval Study

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Submitted by Anonymous (not verified) on Thu, 02/16/2023 - 19:53
  • Read more about Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Page 41
  • …
  • Next page Next
  • Last page Last
Subscribe to